Besides RAS-activating mutations that confer independence from physiological regulators, human cancers harbor mutations in other RAS network genes such as NF1 (encoding neurofibromin, a RAS GAP), BRAF, or PTPN11 (encoding the SHP2 tyrosine phosphatase involved in RAS activation). This evidence concerns the gene NF1 and cancer.